Skip to content
Screener

Medpace Holdings, Inc. MEDP Business Segments — SG&A

Similar metrics at other companies

Silicon Laboratories logo
SLABReportable Segment — SG&A
$55.49M+33.3%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — SG&A
$124M-6.8%
VGN
VGNTReportable Segment — SG&A
$97M-7.6%
BridgeBio Pharma logo
BBIOReportable Segment — SG&A
$163.9M+54.1%
QXO, Inc. logo
QXOReportable Segment — SG&A
$457.8M+1,792%
Agios Pharmaceuticals logo
AGIOReportable Segment — SG&A
$51.55M+12.4%

Other financials

Income statement

See full
Revenue$707.3M+17.2%
Operating income$146.8M+16.2%
Net income$121.4M+34.5%
EPS (diluted)$4.25+37.1%

Balance sheet

See full
Cash & equivalents$502.7M+985%
Total debt$144.1M-3.8%
Total equity$433.9M+152%
Total assets$2.1B+30.9%

Cash flow

See full
Operating cash flow$162.0M+9.1%
CapEx$23.9M+291%
Free cash flow$138.1M-3.0%

Valuation

See full
Market cap$16.41B+35.7%
Enterprise value$16.05B+31.6%
P/E33.4×+4.5×
P/S5.9×+0.5×

Profitability

See full
Operating margin21%-0.4pp
Net margin17.7%-1.1pp
FCF margin25.4%-0.6pp

Returns & leverage

See full
Return on equity162.2%+72.8pp
Debt / equity0.3×-0.5×
Current ratio0.7×+0.3×

Where this comes from

Reported directly by Medpace Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001668397-26-000025
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Direct service costs, excluding depreciation and amortization - Other segment items (a)39,46637,88473,13771,773
Reimbursed out-of-pocket expenses303,139237,472615,143439,876
Total direct costs505,694423,2981,015,972803,518
Selling, general and administrative48,10346,66496,020104,561
Depreciation6,5556,77713,30613,471
Amortization155237310473
Total operating expenses560,507476,9761,125,608922,023
Income from operations146,824126,335288,327239,858

Item 1. Financial Statements (unaudited)

FAQ

What is Medpace Holdings, Inc.'s business segments — SG&A?
Medpace Holdings, Inc. (MEDP) reported business segments — SG&A of $48.1M in Q2 2026.
How has Medpace Holdings, Inc.'s business segments — SG&A changed year-over-year?
Medpace Holdings, Inc.'s business segments — SG&A increased by 3.1% year-over-year, from $46.66M to $48.1M.
What is the long-term trend for Medpace Holdings, Inc.'s business segments — SG&A?
Over 3 years (2022 to 2025), Medpace Holdings, Inc.'s business segments — SG&A has grown at a 14.6% compound annual growth rate (CAGR), from $131.4M to $197.56M.
What does business segments — SG&A mean?
Encompasses the overhead costs required to support the business segment, including executive management, corporate administrative functions, and business development efforts. These are fixed or semi-fixed costs that support the infrastructure rather than specific project delivery.

Ask your AI about Medpace Holdings, Inc.'s business segments — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude